Furthermore, in a phase II clinical study in KRAS mutant NSCLC patients, selumetinib, another MEK inhibitor, plus docetaxel showed significant improvements in response rate and progression-free survival (PFS) [18], indicating differences in the synergy of MEK inhibitors with gemcitabine compared with taxanes. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.